This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Affymax And Takeda Announce OMONTYS® Data Presentations At The American Society Of Nephrology Kidney Week 2012

Affymax, Inc. (Nasdaq: AFFY) and Takeda Pharmaceuticals U.S.A., Inc. (TPUSA), today announced that multiple abstracts on OMONTYS ® (peginesatide) Injection have been accepted for presentation at the American Society of Nephrology (ASN) Kidney Week 2012 taking place October 30 – November 4, 2012 in San Diego, Calif.

ASN will feature eight OMONTYS presentations (one oral session; seven poster sessions), six of which include data from the Phase 3 clinical program. Three other posters accepted for presentation highlight findings from observational studies on anemia management. Details of the presentations at ASN Kidney Week 2012 follow:

Thursday, November 1, 2012

  • Intravenous (IV) Iron Use in U.S. Hemodialysis Patients Receiving Peginesatide for Anemia Due to Chronic Kidney Disease (Provenzano, et al.)Oral Program # TH-OR097: 4:30 p.m.-6:30p.m.
  • Candidate Action Mechanisms of Peginesatide-Induced Erythropoiesis (Verma, et al.)Poster Board # TH-PO180: 10 a.m.-12 p.m.
  • Efficacy of Peginesatide Versus Epoetin by Baseline Characteristics in Hemodialysis Patients with Anemia Due to Chronic Kidney Disease (CKD) (Levin, et al.)Poster Board # TH-PO823: 10 a.m. -12 p.m.

Friday, November 2, 2012:

  • Initial Dose Stability After Conversion to Peginesatide in Hemodialysis Patients (Schiller, et al.)Poster Board # FR-PO261: 10 a.m.-12 p.m.
  • Peginesatide Immunogenicity in Clinical Studies of Chronic Kidney Disease Patients (Schatz, et al.)Poster Board # FR-PO262: 10 a.m.-12 p.m.
  • Hemoglobin Control and Dose Alterations with Peginesatide Versus Epoetin for Hemodialysis Patients (Spinowitz, et al.)Poster Board # FR-PO260: 10 a.m.-12 p.m.
  • Pharmacokinetics: Pharmacodynamics of Peginesatide in Patients with Chronic Kidney Disease on Dialysis (Czerniak, et al.)Poster Board # FR-PO837: 10 a.m.-12 p.m.
  • Missed Dialysis Sessions Result in Increased Erythropoiesis-Stimulating Agent Use (Bonds, et al.)Poster Board # FR-PO236: 10 a.m.-12 p.m.
  • Persistent Increases in ESA Utilization Following Hospitalization of End-Stage Renal Disease Patients (Bonds, et al.)Poster Board # FR-PO237: 10 a.m.-12 p.m.

Saturday, November 3, 2012:

  • Relationship Between Baseline Inflammatory Status and Cardiovascular Events in Hemodialysis Patients on Peginesatide or Epoetin (Locatelli, et al.)Poster Board # SA-PO629: 10 a.m.-12 p.m.
  • Impact of Frequent Hemoglobin Measurement and Erythropoiesis-Stimulating Agent Dose Titration on Hemoglobin Stability in Dialysis (Szczech, et al.)Poster Board # SA-PO643: 10 a.m.-12 p.m.

*Note: All times are listed in Pacific Time

1 of 5

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,071.22 -41.93 -0.24%
S&P 500 1,977.80 -5.05 -0.25%
NASDAQ 4,505.8520 -6.3420 -0.14%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs